Skip to content

News and
Events

Sort By
  • Newest
  • Oldest
  • A to Z
  • Z to A
Sep 4 2020
Graybug Vision Appoints Robert Breuil as Chief Financial Officer
REDWOOD CITY, Calif., September 4, 2020 - Graybug Vision, Inc. (“Graybug”), a clinical stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the appointment of Robert S. Breuil as Chief Financial Officer with immediate effect. Mr. Breuil succeeds...
Read More
Aug 3 2020
Graybug Vision Appoints Leading Ophthalmologists and Retinal Experts to Join Its Scientific Advisory Board
REDWOOD CITY, Calif., August 3, 2020 – Graybug Vision, Inc. (“Graybug”), a clinical stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the appointment of leading ophthalmologists and retinal experts to provide external scientific counsel on the company’s research and...
Read More
May 18 2020
Graybug Vision Appoints Parisa Zamiri, Physician-Scientist with Deep Expertise in Ophthalmology, as Chief Medical Officer
REDWOOD CITY, Calif., May 18, 2020 – Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat vision-threatening diseases of the retina and optic nerve, appoints Parisa Zamiri M.D., Ph.D. as the company’s Chief Medical Officer, effective June 1, 2020. Dr. Zamiri is a physician-scientist with...
Read More
Apr 21 2020
Nature Communications Highlights Research by Scientists at Graybug Vision and Johns Hopkins University on Sustained Treatment of Retinal Diseases
REDWOOD CITY, Calif., April 21, 2020 – Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat vision-threatening diseases of the retina and optic nerve, announces that a recent publication of the article ‘Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles’ in Nature Communications was recognized...
Read More
Mar 21 2020
Joint Statement on Retina Clinical Trials and COVID-19
To our Colleagues in the Retina Clinical Trials Community: We all take the health and safety of patients, healthcare providers, and our local communities very seriously, and the ongoing pandemic is challenging healthcare delivery and infrastructure worldwide. With that in mind, we wanted to speak with one voice in providing...
Read More
Mar 18 2020
Graybug Vision Concludes Patient Enrollment in its Phase 2b Clinical Trial of GB-102 in Wet Age-Related Macular Degeneration and Accelerates Trial Read-out by Approximately Six Months
REDWOOD CITY, Calif., March 18, 2020 – Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic nerve, today announced the early closing of enrollment in its ALTISSIMO trial. ALTISSIMO is a Phase 2b, 12-month, multicenter, prospective, masked, randomized trial that...
Read More
1 2 5 6